SCHEMBL19259891

SCHEMBL19259891

CC(C)(C)OC(=O)NCc1ncc(Sc2cc(C(=O)O)cc(-c3ccccc3)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 5/20 0.46
LOXL3 P58215 1/20 0.46
PDPK1 O15530 1/20 0.42
LOX P28300 1/20 0.40
HDAC1 Q13547 1/20 0.40
ACACB O00763 4/20 0.39
ACACA Q13085 3/20 0.39
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
LCK P06239 1/20 0.37
GLS O94925 1/20 0.37
KDM4A O75164 1/20 0.36
DYRK1A Q13627 1/20 0.35
CTSS P25774 2/20 0.35
CTSK P43235 2/20 0.35
CTSB P07858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29971303 0.94 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274636 0.91 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274612 0.90 LOXL2 (0.46) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL20983568 0.89 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274318 0.89 LOXL2 (0.46) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274312 0.89 LOXL3 (0.44) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274309 0.88 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274724 0.88 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274732 0.88 LOXL2 (0.45) LOXL2LOXL3PDPK1HDAC1ACACB
SCHEMBL19274640 0.87 LOXL2 (0.40) LOXL2LOXL3PDPK1HDAC1ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416956-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER The Institute of Cancer Research : The Royal Cancer Hospital (GB) 2018-12-26 EP disclosed
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed